A Study Comparing Two Types of Supportive Interventions for Caregivers of Patients With Cancer
NCT ID: NCT04802720
Last Updated: 2025-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
348 participants
INTERVENTIONAL
2021-02-26
2026-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition, this trial will enroll cancer patients in this study to see how their caregivers' participation in ERT-C or CBT may affect the patients' quality of life, stress, and use of healthcare services.
Participants who become bereaved while on study will be given the option to withdraw or remain on study. Assessments for bereaved caregivers will not include the Caregiver Quality of Life Index-Cancer (CQOLC) or the Caregiver Reaction Assessment (CRA).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Emotion Regulation Therapy to Address Distress Among Caregivers
NCT02697357
Treatment Efficacy of Mindfulness-based Cognitive Therapy for Distress in Advanced Cancer Patients
NCT05768256
Cancer Caregiver Burden: Targeting Emotion Regulation in a Trial
NCT02322905
Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer
NCT04298398
Caregivers' and Cancer Survivors' Psychological Distress & Symptom Management
NCT03743415
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Training case participants will be identified and consented onto the study for training purposes only. Participants who are consented as training cases will not be randomized and will not complete any assessments. Data collected on training cases will be used for training and supervision purposes on this study only. These records will not be shown outside of the study supervisors, therapist in training, and staff.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ERT-C: Emotion Regulation Therapy for Cancer Caregivers
Emotion Regulation Therapy for Cancer Caregivers (ERT-C) is an 8-session intervention that builds upon the foundations of CBT-C and addresses earlier motivational processing components of the caregivers context while targeting earlier and later components of internal distress and resultant maladaptive behavioral coping.
Emotion Regulation Therapy for Cancer Caregivers (ERT-C)
The sessions are outlined as follow:
1. psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);
2. attention regulation skills training (Sessions 1-2);
3. training in metacognitive skills (Sessions 3-4);
4. exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);
5. consolidating gains, taking larger proactive steps, and relapse prevention (Session 8).
CBT-C: Cognitive Behavioral Therapy for Cancer Caregivers
Cognitive Behavioral Therapy (CBT-C) is an evidence-based psychotherapeutic approach that is grounded in the cognitive model that purports that a person's emotional, behavioral, and physiological reactions to a situation is based on their appraisal of that situation. The focus of therapy is on changing cognitions and beliefs about a situation and altering automatic behavioral responses evoked by that perception. CBT-C aims to improve emotion regulation by challenging and changing unhelpful cognitions and behaviors and improving personal coping strategies.
Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)
The sessions are outlined as follow:
1. psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);
2. coping effectiveness training (Session 2);
3. identifying unhelpful cognitions and dysfunctional beliefs (Session 3);
4. challenging and restructuring unhelpful cognitions (Session 4);
5. behavioral activation within the limitations of the caregiving context (Session 5);
6. problem-solving (Session 6);
7. communication strategies and assertiveness training (Session 7);
8. consolidating gains, maintenance, and relapse prevention (Session 8).
Training case group
Will be assigned to receive ERT-C only and will not complete questionnaires.
Emotion Regulation Therapy for Cancer Caregivers (ERT-C)
The sessions are outlined as follow:
1. psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);
2. attention regulation skills training (Sessions 1-2);
3. training in metacognitive skills (Sessions 3-4);
4. exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);
5. consolidating gains, taking larger proactive steps, and relapse prevention (Session 8).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)
The sessions are outlined as follow:
1. psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);
2. coping effectiveness training (Session 2);
3. identifying unhelpful cognitions and dysfunctional beliefs (Session 3);
4. challenging and restructuring unhelpful cognitions (Session 4);
5. behavioral activation within the limitations of the caregiving context (Session 5);
6. problem-solving (Session 6);
7. communication strategies and assertiveness training (Session 7);
8. consolidating gains, maintenance, and relapse prevention (Session 8).
Emotion Regulation Therapy for Cancer Caregivers (ERT-C)
The sessions are outlined as follow:
1. psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);
2. attention regulation skills training (Sessions 1-2);
3. training in metacognitive skills (Sessions 3-4);
4. exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);
5. consolidating gains, taking larger proactive steps, and relapse prevention (Session 8).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* As per self-report, age 18 years or older.
* As per self-report, are a caregiver to an MSK or MGH patient with any site/stage of cancer who has received any type of treatment (e.g. curative, palliative) in the past 12 months.
* Experience distress as evidenced by a score of 4 or greater on the Distress Thermometer (DT) and answer "Yes" to at least one of the follow-up questions (i.e. reporting that their distress is related to their caregiving experience, or their distress started or is related to caregiving or has gotten worse since the patient was diagnosed or began treatment. (N/A for training case participants)
* English fluent: Self-report by subject identifying English as the preferred language for healthcare, and self-reported degree of fluency as speaking English "Very well."
* As per self-report, residing in New York or New Jersey (for MSK participants), or Massachusetts (for MGH participants), or have the ability to complete sessions while complying with current telehealth regulations.
Patients:
* Age 18 years or older as per EMR.
* Patient of an eligible caregiver per self-report or the EMR.
* English speaking as per the EMR or self report by subject identifying English as the preferred language for healthcare, and self-reported degree of fluency as speaking English "Very well.".
Exclusion Criteria
* As per self-report, presence of disorder that compromises comprehension of assessments or informed consent information (e.g., dementia).
* As per the judgement of the consenting professional, clinical, PI, and/or as per the medical record, severe psychopathology or cognitive impairment which is likely to interfere with the participation or completion of the protocol or their ability to provide meaningful information
* As per self-report, currently engaged in regular individual psychotherapeutic support (that the participant is unable or unwilling to put on hold for the course of treatment).
* As per self-report, a lifetime history of bipolar disorder, schizophrenia, or schizoaffective disorder.
* As per self-report, has medical condition or medication use known to confound measures of systemic inflammation (e.g., autoimmune disorder, inflammatory disease; uncontrolled thyroid disease; active infection; myocardial infarction or stroke in the last 6 months; Type I diabetes; acute hepatitis; recent vaccination for viral disease). (N/A for training case participants)
* As per self-report, is a regular smoker, defined as having more than 2 cigarettes per day on most days. (N/A for training case participants)
* As per self-report, providing care for a patient who has a caregiver is currently or formerly enrolled in this study ('formerly enrolled' is N/A for training case participants).
* As per self-report, currently enrolled in another study focused on supportive care for caregivers (MGH participants only).
Patients:
* Presence of disorder that compromises comprehension of assessments or informed consent information (e.g., dementia) as per EMR or clinician judgment.
* As per the judgement of the consenting professional, clinical, PI, and/or as per the medical record, severe psychopathology or cognitive impairment which is likely to interfere with the participation or completion of the protocol or their ability to provide meaningful information
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Columbia University
OTHER
University of California
OTHER
University of Michigan
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Nelson, PhD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Irvine (Data and Specimen Analysis Only)
Irvine, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Mount Sinai Hospital (Data Analysis Only)
New York, New York, United States
Columbia University (Data and Specimen Analysis Only)
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-407
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.